Related Experiment Video
Updated: Jun 26, 2026
14:54
An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
Published on: October 20, 2018
In-vitro myoglobin clearance by a novel sorbent system
Viktoriya I Kuntsevich1, Donald A Feinfeld, Pat F Audia
1Department of Medicine, Division of Nephrology and Hypertension, Beth Israel Medical Center, New York, New York 10003, USA.
Summary
A new polymer sorbent, X-Sorb, effectively removed myoglobin from solutions in vitro. This finding suggests X-Sorb’s potential for treating rhabdomyolysis and preventing acute kidney injury.
Area of Science:
- Nephrology
- Biomaterials Science
Background:
- Rhabdomyolysis can cause acute kidney injury due to myoglobin deposition in renal tubules.
- High-flux dialysis may not sufficiently clear myoglobin to prevent kidney damage.
Purpose of the Study:
- To evaluate the in vitro efficacy of a novel polymer sorbent, X-Sorb, in clearing myoglobin from solutions.
- To assess X-Sorb's potential as a therapeutic agent for conditions involving myoglobinemia.
Main Methods:
- Myoglobin solutions in normal saline and human serum were prepared.
- Perfusion of solutions through a column packed with X-Sorb using a peristaltic pump for 4 hours.
- Quantification of myoglobin levels before and after perfusion.
Main Results:
- X-Sorb reduced myoglobin levels in normal saline from 200,000 ng/ml to undetectable (<780 ng/ml) within 4 hours.
- Consistent reduction of >90% in myoglobin concentrations in human serum samples after 4-hour perfusion.
- Demonstrated significant myoglobin clearance capacity of X-Sorb in vitro.
Conclusions:
- X-Sorb exhibits high efficacy in removing myoglobin from both saline and serum solutions in vitro.
- The polymer sorbent X-Sorb shows promise for managing myoglobinemia associated with rhabdomyolysis.
- Further in vivo studies are warranted to confirm the safety and effectiveness of X-Sorb in clinical settings.
